Labopharm down on tramadol news

Labopharm (TSE:DDS) was off C$1.12 (26%) to C$3.13 on Wednesday on news that it plans to run another Phase III trial of its once-daily tramadol to treat osteoarthritis of the knee. DDS said the decision to run the additional Phase III study, which is slated to begin in the fourth quarter, came after discussions with its advisors and FDA following the January release of data from two Phase III trials, in which only one of the studies met the co-primary endpoints (see BioCentury Extra, Wednesday Jan. 28, 2004). ...